… The results from this trial suggest that growth monitoring has a limited effect on children's
height and development, despite improvements in self-reported feeding practices. HBGM had …

Background/Aims: Growth hormone (GH) treatment regimens for children with non-GH-deficient,
idiopathic short stature (ISS) have not been optimized. To compare the efficacy, …

… This international, open-label, randomised controlled trial was done in 13 neonatal intensive
care units in the UK, Spain, and the Netherlands. Infants were included if they were within …

Purpose Pasireotide long-acting release is a somatostatin analog that is indicated for
treatment of patients with acromegaly. This analysis documents the safety of pasireotide long-…

… hormone (GH) regimens have found that GH treatment increased growth velocity and adult
height and was safe. The GH dose was the major predictor of first year growth response. …

… once-daily GH (Genotropin ® ) was initiated, after which participants could enroll into an
open-label extension (OLE) evaluating the safety and efficacy of long-term somatrogon treatment…

Context The MPOWERED core trial (NCT02685709) and open-label extension (OLE) phase
investigated long-term efficacy and safety of oral octreotide capsules (OOC) in patients with …

… -up growth by 2 years of age or older account for approximately 20% of all cases of growth
failure. SGA is a heterogeneous condition resulting from impaired intrauterine growth, either …

… This was an open-label randomized control trial that was conducted at a tertiary centre from
February 2018 to June 2020. Adult patients younger than 80 years, with DC of any etiology …

… Growth hormone (GH) replacement therapy is a successful treatment for children and adults
with GH deficiency as well as for growth retardation in children with chronic renal disease …